相似文献
1
Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
Neuro Oncol. 2018 Jan 22;20(2):203-214. doi: 10.1093/neuonc/nox134.
2
Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Clin Cancer Res. 2018 May 1;24(9):2159-2170. doi: 10.1158/1078-0432.CCR-17-2256. Epub 2018 Feb 20.
3
RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines.
Neuro Oncol. 2011 Dec;13(12):1265-76. doi: 10.1093/neuonc/nor129. Epub 2011 Aug 31.
4
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Clin Cancer Res. 2008 Dec 15;14(24):8132-42. doi: 10.1158/1078-0432.CCR-08-1665.
5
Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Cancer Biol Ther. 2015;16(2):233-43. doi: 10.4161/15384047.2014.987548.
6
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Cancer Res. 2013 Feb 15;73(4):1340-51. doi: 10.1158/0008-5472.CAN-12-1365. Epub 2012 Dec 12.
7
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Cancer Chemother Pharmacol. 2014 May;73(5):983-90. doi: 10.1007/s00280-014-2430-z. Epub 2014 Mar 14.
8
The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836.
9
BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Cancer Res. 2008 Apr 15;68(8):2944-51. doi: 10.1158/0008-5472.CAN-07-2508.
10
Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
Target Oncol. 2019 Oct;14(5):563-575. doi: 10.1007/s11523-019-00662-4.
引用本文的文献
1
Dual Targeting of Aurora-A and Bcl-xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer.
Cancer Sci. 2025 Jul;116(7):1823-1835. doi: 10.1111/cas.70072. Epub 2025 Mar 30.
2
Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family.
Anticancer Agents Med Chem. 2025;25(3):164-178. doi: 10.2174/0118715206320224240910054728.
3
Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.
Br J Cancer. 2024 Sep;131(4):763-777. doi: 10.1038/s41416-024-02740-5. Epub 2024 Jun 28.
4
Overcoming Treatment Resistance in Medulloblastoma: Underlying Mechanisms and Potential Strategies.
Cancers (Basel). 2024 Jun 18;16(12):2249. doi: 10.3390/cancers16122249.
5
Regulated cell death in glioma: promising targets for natural small-molecule compounds.
Front Oncol. 2024 Jan 18;14:1273841. doi: 10.3389/fonc.2024.1273841. eCollection 2024.
6
The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
Cell Death Dis. 2023 Oct 28;14(10):705. doi: 10.1038/s41419-023-06231-y.
7
Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
Sci Rep. 2022 Oct 22;12(1):17729. doi: 10.1038/s41598-022-20910-4.
8
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.
Cancers (Basel). 2021 Dec 23;14(1):51. doi: 10.3390/cancers14010051.
9
GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models.
Cancers (Basel). 2021 Nov 25;13(23):5939. doi: 10.3390/cancers13235939.
10
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Neuro Oncol. 2022 Mar 12;24(3):414-426. doi: 10.1093/neuonc/noab207.
本文引用的文献
1
Pediatric high-grade glioma: biologically and clinically in need of new thinking.
Neuro Oncol. 2017 Feb 1;19(2):153-161. doi: 10.1093/neuonc/now101.
2
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4.
3
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.
4
Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.
Curr Opin Pharmacol. 2015 Aug;23:74-81. doi: 10.1016/j.coph.2015.05.014. Epub 2015 Jun 14.
5
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.
6
Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
Neuro Oncol. 2015 Jun;17(6):882-8. doi: 10.1093/neuonc/nov017. Epub 2015 Feb 16.
7
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Cancer Cell. 2015 Jan 12;27(1):72-84. doi: 10.1016/j.ccell.2014.11.002. Epub 2014 Dec 18.
8
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Neuro Oncol. 2014 Oct;16 Suppl 4(Suppl 4):iv1-63. doi: 10.1093/neuonc/nou223.
9
Small-molecule Bax agonists for cancer therapy.
Nat Commun. 2014 Sep 17;5:4935. doi: 10.1038/ncomms5935.
10
Bcl-xL controls a switch between cell death modes during mitotic arrest.
Cell Death Dis. 2014 Jun 12;5(6):e1291. doi: 10.1038/cddis.2014.251.
Zotero 插件